Cholangiocarcinoma

3 articles published between March 11, 2026 and September 4, 2026.

Covered in Climate & Health, Policy and Science.

EPA finds 1,2-dichloropropane, a known carcinogen, an unreasonable health risk

In a draft TSCA evaluation open for comment until 3 November, EPA preliminarily found the industrial solvent poses unreasonable risk to health. IARC classifies it as a Group 1 human carcinogen.

3 min read

THE DRUG DOCKET

A bile-duct cancer with a rare gene fusion gets its first targeted drug

Bizengri now covers NRG1-fusion cholangiocarcinoma, a mutation found in a fraction of a fraction of cases. The evidence is 19 patients, of whom about a third responded.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Drug therapy before surgery delayed relapse in high-risk bile-duct cancer

In a Chinese phase 2–3 trial, neoadjuvant chemotherapy, lenvatinib and a PD-1 antibody before liver surgery lifted median event-free survival to 18.0 months from 8.7. The survival signal was not yet conclusive.

3 min read

This page indexes this newspaper’s reporting on Cholangiocarcinoma. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.